TiGenix NV , an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platform of allogeneic, expanded adipose-derived stem cells in inflammatory and autoimmune diseases, issued today its business and financial update for the third quarter of 2014. "In the third quarter of this year, TiGenix has continued to prepare its most advanced product candidate for market readiness and commercialisation," said Eduardo Bravo, CEO of TiGenix.
http://ift.tt/1tDDT2y
http://ift.tt/1tDDT2y
No comments:
Post a Comment